Literature DB >> 26383054

Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanoma.

Kilian Wistuba-Hamprecht1,2, Svetlana Di Benedetto1, Bastian Schilling3, Antje Sucker3, Dirk Schadendorf3, Claus Garbe2, Benjamin Weide2,4, Graham Pawelec1.   

Abstract

Human T cells carrying γδ T-cell receptors (TCRs) represent a minor population relative to those with αβ TCRs. There has been much interest recently in the possibility of using these γδ T-cells in cancer therapy because they can kill tumor cells in vitro in an MHC-unrestricted manner, and possess potential regulatory capability and antigen-presenting capacity. The presence of γδ T-cells in late-stage melanoma patients and their relationship with survival has not been extensively explored, although relatively lower percentages of total γδ T-cells and Vδ2+ cells have been reported. Here, we present a detailed analysis of associations of γδ T-cell subsets and differentiation stages with survival in Stage IV patients, compared with CD4+ and CD8+ αβ T-cells. We found an increased Vδ1:Vδ2-ratio and a decreased CD4:CD8-ratio in patients compared to healthy controls, on the basis both of relative frequencies and absolute cell counts per μL blood. Nonetheless, Kaplan-Meier analyses showed that a higher than median frequency of Vδ1+ cells was negatively associated with survival, whereas there were no positive or negative associations with frequencies of Vδ2+ cells. Correlations of cell differentiation status with survival revealed a negative association of early-differentiated Vδ1+ T cells with survival, both on the basis of relative frequencies and absolute counts. There was also a positive correlation between the frequencies of early-differentiated CD8+ αβ T-cells and survival. Our findings suggest peripheral blood frequencies of Vδ1+ T-cells as a potential prognostic marker in melanoma. The mechanisms by which higher abundance of Vδ1+ cells are associated with poorer survival require determination.
© 2015 UICC.

Entities:  

Keywords:  biomarker; malignant melanoma; survival; γδ T-cells

Mesh:

Substances:

Year:  2015        PMID: 26383054     DOI: 10.1002/ijc.29818

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Authors:  Kilian Wistuba-Hamprecht; Alexander Martens; Karin Haehnel; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Anis Larbi; Bastian Schilling; Dirk Schadendorf; Jedd D Wolchok; Christian U Blank; Graham Pawelec; Claus Garbe; Benjamin Weide
Journal:  Eur J Cancer       Date:  2016-07-09       Impact factor: 9.162

Review 2.  γδ T Cells: Unexpected Regulators of Cancer Development and Progression.

Authors:  Christopher Fleming; Samantha Morrissey; Yihua Cai; Jun Yan
Journal:  Trends Cancer       Date:  2017-07-17

3.  The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome.

Authors:  Pauline Girard; Julie Charles; Camille Cluzel; Emmanuelle Degeorges; Olivier Manches; Joel Plumas; Florence De Fraipont; Marie-Therese Leccia; Stephane Mouret; Laurence Chaperot; Caroline Aspord
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

4.  Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

Authors:  Kilian Wistuba-Hamprecht; Alexander Martens; Florian Heubach; Emanuela Romano; Marnix Geukes Foppen; Jianda Yuan; Michael Postow; Phillip Wong; Domenico Mallardo; Bastian Schilling; Anna Maria Di Giacomo; Amir Khammari; Brigitte Dreno; Michele Maio; Dirk Schadendorf; Paolo A Ascierto; Jedd D Wolchok; Christian U Blank; Claus Garbe; Graham Pawelec; Benjamin Weide
Journal:  Eur J Cancer       Date:  2017-02-04       Impact factor: 9.162

5.  Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.

Authors:  Quentin Klopfenstein; Valentin Derangère; Laurent Arnould; Marion Thibaudin; Emeric Limagne; Francois Ghiringhelli; Caroline Truntzer; Sylvain Ladoire
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 6.  Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment.

Authors:  Alessandro Poggi; Massimo Giuliani
Journal:  Vaccines (Basel)       Date:  2016-11-08

Review 7.  Gamma-delta (γδ) T cells: friend or foe in cancer development?

Authors:  Yijing Zhao; Chao Niu; Jiuwei Cui
Journal:  J Transl Med       Date:  2018-01-10       Impact factor: 5.531

Review 8.  Does Regular Exercise Counter T Cell Immunosenescence Reducing the Risk of Developing Cancer and Promoting Successful Treatment of Malignancies?

Authors:  James E Turner; Patricia C Brum
Journal:  Oxid Med Cell Longev       Date:  2017-07-02       Impact factor: 6.543

9.  Peripheral blood T-cell signatures from high-resolution immune phenotyping of γδ and αβ T-cells in younger and older subjects in the Berlin Aging Study II.

Authors:  Kilian Wistuba-Hamprecht; Karin Haehnel; Nicole Janssen; Ilja Demuth; Graham Pawelec
Journal:  Immun Ageing       Date:  2015-12-04       Impact factor: 6.400

10.  Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging.

Authors:  Martine J Kallemeijn; François G Kavelaars; Michèle Y van der Klift; Ingrid L M Wolvers-Tettero; Peter J M Valk; Jacques J M van Dongen; Anton W Langerak
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.